AIM
TCON

Acrospire Investment Management’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Acrospire Investment Management’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2
Closed -$1K – 1541
2017
Q2 		$1K Sell
2
-4
-67% -$2.44K ﹤0.01% 2111
2017
Q1 		$4K Buy
+6
New +$5.38K ﹤0.01% 2049

Other funds holding TCON

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acrospire Investment Management's TCON Position: Q3 2017 in Review

Acrospire Investment Management sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q3 2017, closing a stake of 2 shares — an estimated $1K sold.

Acrospire Investment Management first reported a position in TCON in Q1 2017 and held it in 2 quarters. The position peaked at $4K in Q1 2017. 26 funds tracked by Wall St. Rank hold TCON as of Q3 2017.

  • Acrospire Investment Management reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 2 TRACON Pharmaceuticals, Inc. Common Stock shares in Q3 2017, an estimated $1K.
  • Acrospire Investment Management first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Acrospire Investment Management's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $4K in Q1 2017.
  • 26 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.